Elan and its research partner Biogen Idec (listed on the Nasdaq) announced today that its Phase III Tysabri Affirm monotherapy trial was a success.
The two-year trial aimed to slow the progression of disability in patients with relapsing forms of multiuple sclerosis.
CONNECT WITH US TODAY
Be the first to know the latest news and updates
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Push Notifications
By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.
Sign UpNewsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Newsletter
Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.
Sunday, February 8, 2026 - 9:00 PM
Monday, February 9, 2026 - 6:00 AM
Monday, February 9, 2026 - 6:00 AM
